FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

4/11/25 8:30:00 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $FBLG alert in real time by email

HOUSTON, April 11, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (NASDAQ:FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 240+ patents issued and pending for the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics, will present on FibroBiologics' unique fibroblast cell-based approach for the potential treatment of chronic diseases at The Cell & Gene Meeting On The Mediterranean (Med) in Rome, Italy, from April 15-17, 2025. The Cell & Gene Meeting on the Med is the leading conference bringing together the Advanced Therapy Medicinal Products community from Europe and beyond.

Details of the conference and presentations are as follows:

The Cell & Gene Meeting On The Med

Presentation Title: Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases

Presenter: Hamid Khoja, Ph.D., Chief Scientific Officer, FibroBiologics

Location: Salone dei Cavalieri, Section 2

Date and Time: Wednesday, April 16 at 9:00 AM CEST

For more information, please visit FibroBiologics' website or email FibroBiologics at: [email protected].

About FibroBiologics

Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 240+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.

General Inquiries:

[email protected]

Investor Relations:

Nic Johnson

Russo Partners

(212) 845-4242

[email protected]

Media Contact:

Liz Phillips

Russo Partners

(347) 956-7697

[email protected]

Get the next $FBLG alert in real time by email

Date

Price Target

Rating

Analyst

12/12/2024

$12.00

Buy

Rodman & Renshaw

10/30/2024

$12.00

Buy

H.C. Wainwright

9/24/2024

$12.00

Buy

Maxim Group

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

4/11/25 8:30:00 AM ET

$FBLG

Biotechnology: Pharmaceutical Preparations

Health Care

Get the next $FBLG alert in real time by email

Details of the conference and presentations are as follows:

The Cell & Gene Meeting On The Med

Presentation Title: Restoring Immune system homeostasis using a fibroblast cell-based therapeutic targeting three chronic inflammation-mediated diseases

Presenter: Hamid Khoja, Ph.D., Chief Scientific Officer, FibroBiologics

Location: Salone dei Cavalieri, Section 2

Date and Time: Wednesday, April 16 at 9:00 AM CEST

For more information, please visit FibroBiologics' website or email FibroBiologics at: [email protected].

About FibroBiologics

General Inquiries:

[email protected]

Investor Relations:

Nic Johnson

Russo Partners

(212) 845-4242

[email protected]

Media Contact:

Liz Phillips

Russo Partners

(347) 956-7697

[email protected]

Get the next $FBLG alert in real time by email

Date

Price Target

Rating

Analyst

12/12/2024

$12.00

Buy

Rodman & Renshaw

10/30/2024

$12.00

Buy

H.C. Wainwright

9/24/2024

$12.00

Buy

Maxim Group

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$FBLG

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$FBLG

$FBLG
Press Releases

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

$FBLG
Analyst Ratings

Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

H.C. Wainwright initiated coverage on FibroBiologics with a new price target

Maxim Group initiated coverage on FibroBiologics with a new price target

$FBLG
SEC Filings

FibroBiologics Inc. filed SEC Form 8-K: Leadership Update

SEC Form 10-K filed by FibroBiologics Inc.

FibroBiologics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

$FBLG
Insider Purchases

Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER O'Heeron Pete bought $19,531 worth of shares (51,500 units at $0.38), increasing direct ownership by 0.87% to 5,958,147 units (SEC Form 4)

Chief Financial Officer Davis Jason bought $28,973 worth of shares (70,000 units at $0.41) (SEC Form 4)

$FBLG
Insider Trading

Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER O'Heeron Pete bought $19,531 worth of shares (51,500 units at $0.38), increasing direct ownership by 0.87% to 5,958,147 units (SEC Form 4)

Chief Financial Officer Davis Jason bought $28,973 worth of shares (70,000 units at $0.41) (SEC Form 4)

$FBLG
Leadership Updates

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

FibroBiologics Set to Join Russell 2000® Index

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $FBLG

FibroBiologics to Present at The Cell & Gene Meeting on the Mediterranean

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for $FBLG

$FBLG Press Releases

FibroBiologics Completes Site Onboarding for Phase 1/2 Clinical Trial for CYWC628 for the Treatment of Refractory Diabetic Foot Ulcers

Cell Therapies Moving From Lab to Factory Floor, and the Stocks Behind Them

FibroBiologics, Inc. Announces Issuance of U.S. Patent Covering Fibroblast Cell Therapy for the Treatment of Osteoporosis

$FBLG Analyst Ratings

Rodman & Renshaw initiated coverage on FibroBiologics with a new price target

H.C. Wainwright initiated coverage on FibroBiologics with a new price target

Maxim Group initiated coverage on FibroBiologics with a new price target

$FBLG SEC Filings

FibroBiologics Inc. filed SEC Form 8-K: Leadership Update

SEC Form 10-K filed by FibroBiologics Inc.

FibroBiologics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

$FBLG Insider Purchases

Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER O'Heeron Pete bought $19,531 worth of shares (51,500 units at $0.38), increasing direct ownership by 0.87% to 5,958,147 units (SEC Form 4)

Chief Financial Officer Davis Jason bought $28,973 worth of shares (70,000 units at $0.41) (SEC Form 4)

$FBLG Insider Trading

Chief Scientific Officer Khoja Hamid bought $11,400 worth of shares (30,000 units at $0.38), increasing direct ownership by 96% to 61,250 units (SEC Form 4)

CHIEF EXECUTIVE OFFICER O'Heeron Pete bought $19,531 worth of shares (51,500 units at $0.38), increasing direct ownership by 0.87% to 5,958,147 units (SEC Form 4)

Chief Financial Officer Davis Jason bought $28,973 worth of shares (70,000 units at $0.41) (SEC Form 4)

$FBLG Leadership Updates

FibroBiologics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

FibroBiologics Appoints Jason D. Davis, CPA, as Chief Financial Officer

FibroBiologics Set to Join Russell 2000® Index

Recent Analyst Ratings for
$FBLG

Recent Analyst Ratings for
$FBLG

$FBLG
Press Releases

$FBLG
Analyst Ratings

$FBLG
SEC Filings

$FBLG
Insider Purchases

$FBLG
Insider Trading

$FBLG
Leadership Updates